Background: Mediastinal radiation therapy (MRT) is a widely used therapy for thoracic malignancies. This therapy has the potential to cause cardiovascular injuries, which may require surgery. The primary aim of this study is to identify the perioperative outcomes of cardiac surgery in patients with a history of MRT. Second, potential predictors of mortality and adverse events were identified. Methods: A retrospective study was conducted among 59 patients with prior MRT who underwent cardiac surgery between December 2009 and March 2015. Included surgeries consisted of procedures through median-and ministernotomy. Baseline, perioperative, and follow-up data were obtained and analyzed.
| INTRODUCTION
Mediastinal radiation therapy (MRT) is a widely used treatment method for thoracic malignancies, especially among patients who suffer from breast cancer or thoracic lymphomas. MRT, alongside surgical procedures and chemotherapeutic treatments, has resulted in an increase in survival in these patients. 1, 2 In turn, this higher survival rate led to an increase in the number of patients with longterm MRT-induced cardiovascular injuries. 3 The damage caused by MRT might occur decades after the initial treatment and is currently the most common cause of nonmalignant mortality in these patients. 4 The pathogenesis of MRT-induced cardiovascular diseases is initiated by radiation-induced inflammation, which subsequently leads to the development of fibrosis and calcification. [5] [6] [7] These histological changes can develop in all components of the heart, which could lead to a wide range of cardiovascular diseases, such as valvular stenosis or regurgitation, coronary artery disease (CAD), cardiomyopathy, pericardial disease, and conduction disorders. 4, 8 Recent studies have shown a high incidence of long-term MRT-induced cardiovascular side effects. For instance, a study among 6039 patients treated for Hodgkin lymphoma showed that 11.6% developed long-term MRT-induced cardiovascular disease. CAD was the most common complication, occurring in 19% of the cases. 9 Additionally, a recent meta-analysis including 1.2 million participants who underwent MRT as a treatment for breast cancer, indicated an increased risk of developing CAD and cardiac mortality (relative risk 1.30 and 1.38, respectively). 10 Previous studies have already shown worse outcomes of cardiac surgery in patients with a history of MRT compared to patients without a history of MRT. [11] [12] [13] [14] [15] [16] [17] These studies mostly researched a subset of cardiac procedures (mostly valvular surgery). We hypothesize that previous MRT is associated with an increased risk of mortality and complications in the entire spectrum of invasive cardiac procedures. The primary aim of this study is to identify the perioperative outcomes of all invasive cardiac procedures in patients with a history of MRT in a single center in The Netherlands. Furthermore, we aim to identify potential predictors of mortality and adverse events in patients undergoing cardiac surgery after MRT. 
| METHODS

| Study parameters
Preoperative patient characteristics, such as comorbidities, data on previous surgeries, laboratory findings (eg, renal and cardiac markers), complications, and echocardiographic findings (eg, left ventricle function and valve function) were obtained. The New York Heart Association classification of each individual was obtained from the health records. Information about the patients' CAD status was obtained from the most recent preoperative coronary angiography. CAD, renal insufficiency, and myocardial infarction were defined according to the definitions of the Society of Thoracic Surgeons (STS) national cardiac surgery database. Euroscore I and Euroscore II were calculated for each patient. 18 Patients who had not been electively admitted for operation, but did require intervention or surgery on the same admission for medical reasons, were classified as urgent.
Periprocedural characteristics, such as data on the operation (eg, type of surgery, cardiopulmonary bypass duration, and aortic cross clamp duration), complications, adverse events, and admission time were collected for each individual. The majority of the patients was transferred to the referring hospital when they were fit to go; therefore, the hospital admission time as reported in this study is the time between surgery and transfer to the referring hospital.
The follow-up of the included patients was conducted until March 2018. The referring hospitals were contacted to collect information about the postoperative period. In case of incomplete information, the patients' general practitioners were contacted. Readmissions, reoperations, other interventions, related events, and mortality were reported for the follow-up period. 
| Statistical analysis
| RESULTS
A total of 59 patients were eligible for inclusion. Baseline characteristics of the patients are shown in Table 1 . The group consisted DOLMACI ET AL.
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predominantly of women (78%) with a median age of 70 years at the moment of surgery. The majority of included patients was diagnosed with breast cancer (n = 43), followed by Hodgkin and non-Hodgkin lymphomas (n = 10 and n = 3, respectively), lung cancer (n = 2), and one case of an extragonadal germ cell tumor located in the thorax.
Twenty-one patients (35.6%) had been treated with chemotherapy in the past. Preoperative echocardiographic findings are shown in Table 2 .
The median time interval between the last received MRT and surgery was 21 years (IQR, 8.75-28). The cardiac surgeries that were most often performed were single-valve repair/replacement, isolated coronary artery bypass grafting (CABG), and CABG combined with a single-valve repair/replacement (31%, 29%, and 22%, respectively). Coronary revascularization was most often achieved by using the vena saphena magna as graft material (n = 31). The second most often employed graft was the left internal mammary artery (n = 22, 27.8%). Both the right internal mammary artery and the radial artery were used only once. Preoperative imaging of the aorta (to detect potential calcifications of the aorta as a result of MRT) was not performed in any patient; however, five patients were operated without the use of cardiopulmonary bypass (off-pump CABG). A total of six (10.2%) patients received a concomitant procedure besides the procedures as described above.
Six of the included cases were a redo sternotomy (10.2%). Another six (10.2%) patients underwent urgent surgery because of acute symptomatic CAD (n = 3), decompensated aortic valve stenosis (n = 2), and one case with native aortic valve endocarditis. Detailed information about the perioperative characteristics is shown in Table 3 .
| POSTOPERATIVE OUTCOMES
| Short-term (in-hospital) mortality
This study did not include any cases of periprocedural mortality (within 24 hours after surgery). A total of six patients (all female) died during their stay in the hospital, of which four within 30 days after surgery. Three out of four of these patients were treated for breast cancer in the past. All short-term mortalities were cardiovascular related. Detailed information about the in-hospital deaths can be found in Table 4 . 
T A B L E 1 Baseline characteristics
| Short-term (in-hospital) complications and reinterventions
Postoperatively, nine (15.3%) rethoracotomies had to be performed ( 
| IDENTIFIED RISK FACTORS
| Mortality
To identify risk factors for mortality, Cox proportional hazard modeling was performed ( difference in mortality between various types of cancer, analyses showed no significant differences of mortality outcomes.
| Adverse events
Patients who were diagnosed with chronic obstructive pulmonary disease (COPD) had a longer intensive care unit (ICU) stay, compared to those without COPD (P = .034). Furthermore, Euroscore II was associated with a longer ICU stay (P = .035). Further analyses looked into malignancy-related adverse events. These results indicated that those patients with breast cancer in the past had a higher incidence of postoperative kidney failure (P = .001). No differences were found in postoperative outcomes between patients with left-sided vs rightsided breast cancer (P > .05). Furthermore, a history of chemotherapy was not associated with worse outcomes (P > .05). The time between MRT and surgery also showed no association with adverse outcomes (P > .05). Preoperative ejection fraction (EF) or valve-related problems were not related to adverse events. However, selection bias could have painted a wrong image, since the majority of the patients in this study (71.2%) had a good EF (>50%) before surgery.
| DISCUSSION
The primary aim of this study was to identify the perioperative outcomes of invasive cardiac procedures in patients with a history of MRT. Over the last decades, the number of patients surviving cancer has risen dramatically, at the price of long-term MRT-induced cardiovascular complications. 3, 19 MRT inflicts radiation-induced inflammation in the radiation field, which subsequently leads to the development of fibrosis and calcification. Depending on the cardiac structures captured in the radiation field, this could result in problems like valvular damage, accelerated CAD, and conduction disorders. [5] [6] [7] These comorbidities can affect the perioperative outcomes of surgery Recent evidence shows that these calculators might not be as reliable in predicting the mortality of patients with a history of MRT undergoing cardiac surgery as previously expected. 14, 15, 17 The mortality in the current study was higher than estimated by the Euroscore II (10.2% vs 3.4%), matching the results found by Ghoneim et al 15 and
Wu et al. 17 This implicates that the Euroscore II is suboptimal in calculating the risk of mortality in patients with a history of MRT.
In-hospital mortality rates after cardiac surgery in a general patient population without previous MRT varies between 3% and 4%. 18, 21 In the current study, the in-hospital mortality was substantially higher (10.2%). Previous studies, which compared the data of patients undergoing valvular surgery with previous MRT vs matched groups without MRT, showed higher rates of in-hospital mortality and worse survival of patients with MRT. 13, 14 Other studies that looked at the outcomes of cardiac surgery in patients with MRT in the past showed in-hospital mortality rates ranging between 2.3% and 13.6%. [11] [12] [13] [14] [15] [16] [17] Long-term survival shows a variation between the different studies (all with different follow-up periods), ranging from 32% to 80%. [11] [12] [13] [14] [15] [16] [17] The survival at the end of this study was 72.9% at a median follow-up of 52 months. The exact reason of this high survival is unknown. A possible explanation is the high amount of patients with breast cancer in this study. Chang et al 11 showed in a previous study that these patients are more likely to have a positive outcome than patients with Hodgkin lymphomas. Yet, the analysis of the current study showed no significant differences in mortality between the different types of cancer. Of the 16 patients who died in this study, 10 were diagnosed with breast cancer vs 4 with Hodgkin lymphoma. Differences in the treatment regimen could explain this inconsistency. In the past, more aggressive and excessive strategies of MRT were custom. 22 The sample of Chang et al consisted of patients who had received tangential (peripheral) radiation therapy, while the sample of this study mainly consisted of patients who underwent MRT long before surgery (mean interval of MRT-surgery:
16 years). On top of that analyses showed no difference in outcomes between left-sided and right-sided breast cancer, indicating that the patients with breast cancer in this study did not receive tangential radiation therapy.
| Limitations
As with all retrospective and observational studies, this study is subject to various limitations due to the research design. In some cases, the health records did not contain all of the desired information. A large number of patients (77.2%) were referred from other hospitals. This complicated the collecting of patient data, especially during the follow-up period. Also, the retrospective design of this study made it impossible to collect complete data of the radiation therapy that the patients had received in the past. The gathering of data regarding the received radiation dose-which may have had a major influence on the surgery outcomes-was especially difficult. Since this was a single-center study, only a small number of patients were eligible for inclusion. A future multicenter study should be initiated to create a larger group and draw more generalizable conclusions.
| CONCLUSION
This retrospective study showed that short-term mortality is high in patients with a history of MRT. While surgery-related events were the main cause of short-term mortality, malignancy-related events were the main cause of late mortality during the follow-up.
Furthermore, this study indicated that the actual mortality in patients with a history of MRT is higher than predicted by the Euroscore II. This implicates that physicians should be careful when applying mortality risk calculators, since they tend to underestimate the mortality risk of patients with a history of MRT. Finally, a previous stroke and a lower preoperative GFR were identified as a risk factor for all-cause mortality.
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